Clinical Trial Update: A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing trastuzumab deruxtecan to CDK4/6 inhibitors in non-luminal A, ER-positive/HER2-low metastatic breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)
• IBRANCE (PALBOCICLIB)
• KISQALI (ribociclib)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Danish Breast Cancer Cooperative Group | Conditions: Metastatic Breast Cancer, ER-positive Breast Cancer | Phase 3 | Status: WITHDRAWN